Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Sector: Pharmaceutical Preparations
Industry: Medical - Devices
Perspective Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 114.15M shares outstanding
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues.
The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Leadership
Frank Morich, M.D., Ph.D.
Member
Heidi Henson
Member
Johan (Thijs) Spoor
Member
Lori A. Woods
Chair
Employees
166
Country
US
Sector
Healthcare
Website
perspectivetherapeutics.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| 10% Owner | Sale | 167.1K | $526.1K | Sep 4, 2026 | |
| 10% Owner | Sale | 80.8K | $250.9K | Sep 3, 2026 | |
| 10% Owner | Sale | 42.1K | $131.2K | Sep 2, 2026 | |
| 10% Owner | Sale | 35.8K | $111.6K | Sep 1, 2026 | |
| 10% Owner | Sale | 35.8K | $111.6K | Sep 1, 2026 | |
| 10% Owner | Sale | 78.1K | $245.6K | Aug 31, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Lantheus Holdings, Inc. 10% Owner | 11.6M | 10.1% | FORM 4 |
BlackRock, Inc. | 9.5M | 8.3% | 13F |
Lantheus Alpha Therapy, LLC · joint filing· may incl. warrants· filed Sep 2026 | 8.7M | 7.7% | 13D |
TCG Crossover Management, LLC | 7.9M | 6.9% | 13F |
Commodore Capital LP | 6.3M | 5.6% | 13F |
Avidity Partners Management LP | 6.3M | 5.5% | 13F |
STATE STREET CORP | 6.1M | 5.3% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Apr 2026 | 5.3M | 4.6% | 13G |
MILLENNIUM MANAGEMENT LLC | 4.9M | 4.3% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 4.4M | 3.9% | 13F |
Insiders
- Lantheus Alpha Therapy, LLC10% Owner
- Lantheus Holdings, Inc.10% Owner
- Woods Lori ADirector
- HENSON HEIDIDirector
- Williamson Robert F IIIDirector
- Morich FrankDirector
- Martinez Maria EDirector
- Spoor Johan M.Chief Executive Officer
- Hunt Jonathan RobertChief Accounting Officer
- Puhlmann MarkusChief Medical Officer
based on 114.15M shares outstanding
30d Avg
2.26M
60d Avg
2.25M
90d Avg
1.84M